Evaluation of Matrix Metalloproteinase 2 and 9 Activity in Patients with Prostate Cancer and Benign Prostate Hyperplasia Compared with Healthy Individuals
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-6 (e12)
https://doi.org/10.22037/amls.v6.32378
Abstract
Background and Aim: Prostate cancer (PC) is one of the most prevalent cancers with high mortality and morbidity in men, which can be treated in different ways before the progression and metastasis to distant organs. Destruction of extracellular matrix by matrix metalloproteinase (MMP), particularly by the 2 and 9 subtypes, has an important role in the metastasis of PC. We aimed to assess the activity of MMP 2 and 9 and some related metalloproteinases in PC and with benign prostate hyperplasia (BPH) patients in comparison to healthy individuals.
Methods: In this case-control study, 72 individuals referred to Imam Khomeini hospital (Tehran, Iran), have been divided into 3 groups, including PC, BPH, and healthy control. Age and body mass index (BMI) for all groups have been matched. Venous blood samples were used to assess the enzyme activity by the zymography technique.
Results: The activity of MMP-2 and 9 was significantly higher in PC than BPH and control groups. But there was no difference in the activity of enzymes in patients with PC according to the Gleason score.
Conclusion: The results suggested that MMPs activity can be considered a diagnostic marker for PC. However, further studies are required to establish this concept.
*Corresponding Author: Abbas Khonakdar-Tarsi; Email: a.khonakdar@mazums.ac.ir
Please cite this article as: Shojaee M, Mohammadi P, Jafarpour H, Pouriamehr S, Barmaki H, Khonakdar-Tarsi A. Evaluation of Matrix Metalloproteinase 2 and 9 Activity in Patients with Prostate Cancer and Benign Prostate Hyperplasia Compared with Healthy Individuals. Arch Med Lab Sci. 2020;6:1-6(e12). https://doi.org/10.22037/amls.v6.32378
- Benign prostate hyperplasia
- Metalloproteinase
- Prostate Cancer
How to Cite
References
Zamanian Z, Dehghani M, Mohammady H, Rezaeiani M, Daneshmandi H. Investigation of shift work disorders among security personnel. International Journal of Occupational Hygiene. 2012;4:39-42.
Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524.
Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathology international. 2002;52:255-264.
Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Internal and emergency medicine. 2010;5:13-25.
Murphy G, Nagase H. Progress in matrix metalloproteinase research. Molecular aspects of medicine. 2008;29:290-308.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer. 2002;2:161.
Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2005;1755:37-69.
Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2004;1705:69-89.
Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase b) expression in metastasis by murine prostate carcinoma. The American journal of pathology. 1998;152:591.
Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, et al. Expression and activity of matrix metalloproteinases-2 and-9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Archiv. 2004;444:518-26.
Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, et al. Matrix metalloproteinases as diagnostic (mmp-13) and prognostic (mmp-2, mmp-9) markers of prostate cancer. Urological research. 2005;33:44-50.
Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Significance of mmp-2 expression in prostate cancer: An immunohistochemical study. Cancer research. 2003;63:8511-5.
Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: Identification of patients with poor prognosis by immunohistochemistry. Human pathology. 2008;39:731-9.
Fridman R, Toth M, Peña D, Mobashery S. Activation of progelatinase b (mmp-9) by gelatinase a (mmp-2). Cancer research. 1995;55:2548-55.
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967
Michael A, Relph K, Pandha H. Emergence of potential biomarkers of response to anti‐angiogenic anti‐tumour agents. International journal of cancer. 2010;127:1251-8.
Cross MJ, Claesson-Welsh L. Fgf and vegf function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends in pharmacological sciences. 2001;22:201-7.
Cooke JP, Losordo DW. Nitric oxide and angiogenesis. 2002;105:2133-5.
Nissen LJ, Cao R, Hedlund E-M, Wang Z, Zhao X, Wetterskog D, et al. Angiogenic factors fgf2 and pdgf-bb synergistically promote murine tumor neovascularization and metastasis. The Journal of clinical investigation. 2007;117:2766-77.
Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. The Journal of clinical investigation. 1999;103:1237-41.
Vanderslice P, Munsch CL, Rachal E, Erichsen D, Sughrue KM, Truong AN, et al. Angiogenesis induced by tumor necrosis factor-agr; is mediated by α4 integrins. Angiogenesis. 1998;2:265-5.
Trudel D, Fradet Y, Meyer F, Têtu B. Matrix metalloproteinase 9 is associated with gleason score in prostate cancer but not with prognosis. Human pathology. 2010;41:1694-701.
González RI, Gil UR, Del Fresno MR, Fernández GI, Tardón A. 537 the value of plasmatic determination of matrix metalloproteinase 9 as a diagnostic marker in prostate cancer. Closing the controversies. European Urology Supplements. 2012;11:e537.
Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of mmp‐2 and mmp‐9 production by prostate cancer cell lines via activation of protease‐activated receptors. The Prostate. 2004;60:168-74.
Hamdy F, Fadlon E, Cottam D, Lawry J, Thurrell W, Silcocks P, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. British journal of cancer. 1994;69:177.
Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S, et al. Increased matrix metalloproteinase‐9 secretion in short‐term tissue cultures of prostatic tumor cells. International journal of cancer. 1996;69:386-93.
Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer research. 1993;53:4493-8.
Stearns ME, Wang M. Type iv collagenase (mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer research. 1993;53:878-83.
Monfironi R, Fabris G, Lucarini G, Biagini G. Location of 72-kd metalloproteinase (type iv collagenase) in untreated prostatic adenocarcinoma. Pathology-Research and Practice. 1995;191:1140-6.
Montironi R, Lucarini G, Castaldini C, Galluzzi C, Biagini G, Fabris G. Immunohistochemical evaluation of type iv collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer research. 1996;16:2057-62.
Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mrna for matrix metalloproteinase‐2 (mmp‐2) and tissue inhibitor of matrix metalloproteinase‐2 (timp‐2) in human benign and malignant prostatic tissue. The Prostate. 2000;42:18-25.
Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, et al. Membrane type 1-matrix metalloproteinase (mt1-mmp) and mmp-2 immunolocalization in human prostate: Change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clinical Cancer Research. 1999;5:4105-10.
- Abstract Viewed: 120 times
- PDF Downloaded: 92 times